Sökning: WFRF:(Wadhwa A)
> (2001-2004) >
Incidence of GM-CSF...
Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.
-
- Ullenhag, G (författare)
- Uppsala universitet,Enheten för onkologi,Institutionen för onkologi, radiologi och klinisk immunologi
-
- Bird, C (författare)
- Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Herts, United Kingdom
-
- Ragnhammar, P (författare)
- Karolinska Institutet
-
visa fler...
-
- Frödin, J E (författare)
- Karolinska Institutet,Stockholm
-
- Strigård, Karin (författare)
- Karolinska Institutet
-
- Olsterborg, A (författare)
- Karolinska Institutet
-
- Thorpe, R (författare)
- Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Herts, United Kingdom
-
- Mellstedt, H (författare)
- Karolinska Institutet,CCk, Stockholm
-
- Wadhwa, M (författare)
- Division of Immunobiology, National Institute for Biological Standards and Control, Potters Bar, Herts, United Kingdom
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2001
- 2001
- Engelska.
-
Ingår i: Clinical Immunology. - : Elsevier BV. - 1521-6616 .- 1521-7035. ; 99, s. 65-
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- We have assessed the immunogenicity profile of GM-CSF in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GM-CSF (Escherichia coli-derived) combination therapy. Metastatic CRC patients received a colon carcinoma-reactive antibody and high doses of GM-CSF (425--500 microg/day for 10 days), while other CRC patients and those with myeloma received low doses of GM-CSF (75--80 microg/day for 4 days) as an adjuvant along with appropriate tumor antigens. We found that 55% of the patients (11/20) given high doses of GM-CSF developed GM-CSF-reactive antibodies in comparison with an incidence of only 16% (4/25) in patients given low doses of GM-CSF. None of the patients developed neutralizing antibodies and so the biological effects of GM-CSF were not compromised. A majority of patients (80%) (36/45) also developed antibodies to E. coli proteins that were present as trace contaminants in the GM-CSF product. Treatment with recombinant GM-CSF products, therefore, may induce antibodies against this cytokine depending on the regimen and the amounts used. In this study, multiple immunizations with low doses of GM-CSF was associated with a low incidence of GM-CSF antibodies, which did not neutralize the effect of the cytokine. This therapeutic strategy was effective in inducing adjuvant-type effects and needs to be explored in further clinical trials with this cytokine.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Nyckelord
- GM-CSF
- antibodies
- GM-CSF
- immunostimulation
- cancer
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas